PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling

PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling

Non-alcoholic fatty liver disease (NAFLD) has become a prevalent chronic liver disease, however, drugs to treat this disease are still lacking. Here, the authors show that PPDPF inhibits the development of hepatic steatosis by negatively regulating mTORC1-S6K-SREBP1 signaling, which provides a poten...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ning Ma, Yi-Kang Wang, Sheng Xu, Qian-Zhi Ni, Qian-Wen Zheng, Bing Zhu, Hui-Jun Cao, Hao Jiang, Feng-Kun Zhang, Yan-Mei Yuan, Er-Bin Zhang, Tian-Wei Chen, Ji Xia, Xu-Fen Ding, Zhen-Hua Chen, Xiu-Ping Zhang, Kang Wang, Shu-Qun Cheng, Lin Qiu, Zhi-Gang Li, Yong-Chun Yu, Xiao-Fan Wang, Bin Zhou, Jing-Jing Li, Dong Xie
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/8537535d3b06469c9a7a4a00e3cfe23a
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:Non-alcoholic fatty liver disease (NAFLD) has become a prevalent chronic liver disease, however, drugs to treat this disease are still lacking. Here, the authors show that PPDPF inhibits the development of hepatic steatosis by negatively regulating mTORC1-S6K-SREBP1 signaling, which provides a potential therapeutic candidate for NAFLD treatment.

Documents similaires